CT109-ADC
/ Stromatis Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 05, 2024
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells.
(PubMed, Curr Cancer Drug Targets)
- "These data suggest that further preclinical and clinical development of CT109-SN-38 is warranted."
Journal • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CEACAM5 • CEACAM6
1 to 1
Of
1
Go to page
1